PwC Romania provided financial and tax due diligence services, as well as transaction support services, to the Polish pharmaceutical group Polpharma in connection with its acquisition of Biofarm, one of Romania’s leading pharmaceutical manufacturers.
Drug manufacturer Biofarm (stock symbol: BIO) ended the first nine months of 2025 with a turnover of RON263.2 million, up 14% against the year-earlier period, and EBITDA climbed 16% to RON109 million.
Shareholders of pharmaceutical producer Biofarm (BIO.RO) approved at their general meeting on April 28 the distribution of the company's net profit of RON74.4 million for 2024, as per a report sent to the Bucharest Stock Exchange.